3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
pirtobrutinib
6
Cyclophosphamide
6
Mycophenolic Acid
5
fludarabine phosphate
4
fludarabine
4
Rituximab
4
Melphalan
4
Azacitidine
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Tacrolimus
3
Mesna
3
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Lenalidomide
2
Cyclosporine
2
Busulfan
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
Blood Specimen Collection
2
Bendamustine Hydrochloride
2
zanubrutinib
1
ruxolitinib
1
ponatinib
1
pembrolizumab
1
nilotinib
1
idelalisib
1
idecabtagene vicleucel
1
cedazuridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
CLR1404
×
1 year
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled